Left ventricular hypertrophy determined by Sokolow-Lyon criteria: a different predictor in women than in men?

R L Antikainen1, T Grodzicki, A J Palmer

  • 1Imperial College Faculty of Medicine, London, UK. Riitta.Antikainen@ouka.fi

Insights

Higher electrocardiogram (ECG) voltage indicates increased cardiovascular disease (CVD) mortality risk. This study shows elevated ECG voltage predicts CVD mortality in both men and women, with women facing higher stroke risk due to left ventricular hypertrophy (LVH).

Area of Science:

  • Cardiology
  • Clinical Electrophysiology
  • Epidemiology

Background:

  • Electrocardiographic left ventricular hypertrophy (ECG LVH) assessment is crucial for cardiovascular risk stratification.
  • The Sokolow-Lyon voltage criteria are commonly used but their clinical utility requires further validation.

Purpose of the Study:

  • To prospectively evaluate the clinical usefulness of Sokolow-Lyon voltage criteria for assessing ECG LVH.
  • To determine the association between baseline ECG voltage and cardiovascular disease (CVD) mortality in a large cohort of hypertensive individuals.

Main Methods:

  • Prospective study of 3,338 women and 3,330 men with hypertension, followed for 11.2 years.
  • Calculated SV1+max (RV5 or RV6) for ECG LVH (sum >= 3.5 mV).
  • Adjusted survival analyses for age, treatment, prior cardiovascular events, race, BMI, smoking, and blood pressure.

Main Results:

  • Increasing baseline ECG voltage independently predicted CVD mortality in both genders.
  • Each 0.1 mV increase in voltage correlated with significant increases in stroke, coronary heart disease (CHD), and CVD mortality.
  • Women with LVH showed a higher risk of stroke mortality, while men had a stronger association between voltage and CHD mortality.

Conclusions:

  • Greater baseline ECG voltage sum is directly associated with increased CVD mortality risk.
  • LVH contributes significantly to population-attributable stroke and CHD mortality, particularly in women.
  • ECG voltage criteria provide valuable prognostic information for cardiovascular events in hypertensive patients.

Related Concept Videos

Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...